This Form 4 filing reports that Stelios Papadopoulos, a director of Exelixis, Inc., received 8,367 restricted stock units (RSUs) on May 27, 2026. The RSUs were granted under the company's 2017 Equity Incentive Plan and represent the economic equivalent of common stock. The award will vest in full on May 27, 2027, conti...

This filing details a grant of 8,367 restricted stock units (RSUs) to George Poste, a director at Exelixis, Inc., on May 27, 2026, under the company's 2017 Equity Incentive Plan. These RSUs are economically equivalent to common stock and will vest fully on May 27, 2027, provided Poste remains in continuous service. The...

Brian J.G. Pereira, a director at PROKIDNEY CORP., acquired 135,000 stock options on May 28, 2026. These options, granted under the company's non-employee director compensation policy, allow the purchase of Class A Common Stock at a price of $1.81 per share. The options are exercisable and will vest in full on the earl...

Uma Sinha, a director at PROKIDNEY CORP., was granted 135,000 stock options on May 28, 2026. These options, exercisable at $1.81 per share, are for the company's Class A Common Stock and will vest in full on the earlier of the one-year anniversary of the grant date or the company's next annual general shareholder meeti...

This filing details a transaction by Alla Patlis, Interim Chief Financial Officer & Controller of BRAINSTORM CELL THERAPEUTICS INC. On February 26, 2026, Patlis acquired 100,000 shares of Common Stock via restricted stock units (RSUs) awarded under the company's plan. These RSUs vest in two tranches: 50% upon grant and...

Brian J.G. Pereira, a director at PROKIDNEY CORP., acquired 135,000 stock options on May 28, 2026. These options, granted under the company's non-employee director compensation policy, allow the purchase of Class A Common Stock at a price of $1.81 per share. The options are exercisable and will vest in full on the earl...